WILSON KAREN J 4

What Happened

• Karen J. Wilson, a director of Serina Therapeutics (SER), received a grant/award of 15,250 derivative shares on 2026-06-17. The reported price is $0.00 (i.e., a grant of equity/stock options rather than a cash purchase); no exercise or sale occurred.
• The filing (Form 4) was submitted on 2026-06-22. The grant’s immediate cash value or exercise price is not provided in the report; the instrument is reported as a derivative (not an outright share purchase).

Key Details

• Transaction date: 2026-06-17; Filing date: 2026-06-22.
• Transaction type/code: A (Award/Grant); 15,250 derivative shares reported at $0.00.
• Vesting (F2): Options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to continued service.
• Footnote (F1): This row updates the previously reported number of shares beneficially owned and does not represent an unreported transaction.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Timeliness: The Form 4 was filed five calendar days after the transaction; Form 4s are generally due within two business days, so this filing appears later than the typical deadline.

Context

• This was a time-based equity grant (derivative award/options), not an exercise or sale—meaning no shares were sold and no cash proceeds realized.
• Such grants are common for directors as compensation and do not by themselves indicate buying or selling sentiment; vesting and any future exercise or sale would be reported in later filings.